RE
REPL.US Replimune Group Inc
- Market cap
- USD 1.87B
- P/E
- -
- P/B
- 9.91x
- ROE
- -123.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is REPL.US undervalued?
Graham numberThe Graham number of Replimune Group Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Replimune Group Inc fundamental analysis
No fundamental analysis for Replimune Group Inc yet.
Replimune Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range o…
Full company profileReplimune Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Replimune Group Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -122K | -109K | -148K | -1.81M | -4.14M | -4.58M | -2.45M | -2.66M | -3.50M | - | - |
| Operating Income | -9.65M | -19.2M | -30.9M | -56.2M | -82.8M | -121M | -177M | -235M | -262M | -320M | -249M |
| EBITDA | -8.08M | -16.9M | -30.7M | -52.6M | -78.9M | -117M | -172M | -230M | -256M | -302M | -239M |
| Net Income | -7.70M | -19.7M | -30.8M | -52.6M | -80.9M | -118M | -174M | -216M | -247M | -314M | -254M |
| EPS | -0.25 | -0.64 | -1.33 | -1.54 | -1.75 | -2.26 | -2.99 | -3.24 | -3.07 | -3.38 | -2.41 |
| Balance Sheet | |||||||||||
| Total Assets | 22.8M | 65.2M | 154M | 234M | 543M | 461M | 647M | 488M | 551M | 332M | 374M |
| Total Liabilities | 34.3M | 93.2M | 16.5M | 50.4M | 44.4M | 50.0M | 91.3M | 113M | 135M | 166M | 169M |
| Shareholders' Equity | -11.5M | -28.1M | 138M | 184M | 499M | 411M | 555M | 375M | 416M | 166M | 205M |
| Cash & Short-term Investments | 20.6M | 61.6M | 135M | 169M | 476M | 396M | 583M | 421M | 484M | 269M | 308M |
| Total Debt | - | - | 6.56M | 41.8M | 33.3M | 32.8M | 60.8M | 75.9M | 76.2M | 112M | 127M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.08M | -16.0M | -25.4M | -60.6M | -61.4M | -82.2M | -128M | -185M | -192M | -280M | -247M |
| Capital Expenditure | 238K | 136K | 2.60M | 6.54M | 2.39M | 2.34M | 2.27M | 5.66M | 6.69M | 4.22M | 166K |
| Free Cash Flow | -7.32M | -16.2M | -28.0M | -67.1M | -63.8M | -84.5M | -130M | -191M | -199M | -285M | -247M |
| Ratios | |||||||||||
| ROE | - | - | -22.4% | -28.6% | -16.2% | -28.7% | -31.4% | -57.6% | -59.5% | -188.9% | -123.9% |
| ROA | -33.8% | -30.2% | -20.0% | -22.5% | -14.9% | -25.6% | -27.0% | -44.2% | -44.9% | -94.4% | -67.9% |
| Debt to Equity | - | - | 0.05x | 0.23x | 0.07x | 0.08x | 0.11x | 0.20x | 0.18x | 0.67x | 0.62x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Replimune Group Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 91.7M | 1.98 | - |
| 2020 | USD 28.1M | 0.82 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Replimune Group Inc
- Insiders 1.63%
- Institutions 98.37%
- Public & others 0.00%
- Shares outstanding 94.8M
- Free float 68.2M
Top funds holding REPL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.67M | 2.82% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.42M | 2.55% | +22.54% | Sep 2026 |
| iShares Russell 2000 ETF | 2.06M | 2.17% | 0.00% | Oct 2026 |
| Artisan International Small-Mid Investor | 1.57M | 1.65% | +160.07% | Sep 2026 |
| Fidelity Small Cap Index | 871K | 0.92% | +0.53% | Aug 2026 |
| T. Rowe Price New Horizons | 802K | 0.85% | -11.03% | Sep 2026 |
| iShares Russell 2000 Value ETF | 758K | 0.80% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 682K | 0.72% | -0.19% | Oct 2026 |
| Emerald Growth A | 675K | 0.71% | +8.18% | Sep 2026 |
| F/m Emerald Life Sciences Innovation ETF | 625K | 0.66% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 527K | 0.56% | 0.00% | Aug 2026 |
| Principal SmallCap Growth I Instl | 520K | 0.55% | +29.91% | Sep 2026 |
| Vanguard Russell 2000 ETF | 469K | 0.49% | +3.01% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 468K | 0.49% | 0.00% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 433K | 0.46% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 425K | 0.45% | +0.23% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 409K | 0.43% | +1.63% | Sep 2026 |
| Nuveen Quant Small/Mid Cap Eq R6 | 400K | 0.42% | +3.87% | Sep 2026 |
| Fidelity Extended Market Index | 368K | 0.39% | -0.98% | Sep 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 351K | 0.37% | -0.54% | Oct 2026 |
Top institutions holding REPL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 11.0M | 11.65% | 0.00% | Jun 2026 |
| BlackRock Inc | 8.96M | 9.45% | +43.58% | Jun 2026 |
| RTW INVESTMENTS, LLC | 7.41M | 7.82% | +0.74% | Jun 2026 |
| Ridgeback Capital Investments L.p. | 7.31M | 7.71% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 4.54M | 4.79% | +99.41% | Jun 2026 |
| State Street Corp | 4.44M | 4.68% | +17.39% | Jun 2026 |
| Suvretta Capital Management, LLC | 4.39M | 4.63% | +3.98% | Jun 2026 |
| Boxer Capital Management, LLC | 3.98M | 4.20% | +238.98% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.90M | 3.05% | +4.96% | Jun 2026 |
| FCPM III SERVICES BV | 2.81M | 2.96% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 2.57M | 2.71% | +904.42% | Jun 2026 |
| Logos Global Management LP | 2.50M | 2.64% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 2.32M | 2.45% | +442.47% | Jun 2026 |
| Erste Asset Management GmbH | 2.12M | 2.24% | 0.00% | Jun 2026 |
| Emerald Advisers, LLC | 2.04M | 2.15% | 0.00% | Sep 2026 |
| Geode Capital Management, LLC | 2.04M | 2.15% | +12.97% | Jun 2026 |
| D. E. Shaw & Co LP | 1.79M | 1.89% | -23.39% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.62M | 1.71% | -80.04% | Jun 2026 |
| Emerald Mutual Fund Advisers Trust | 1.60M | 1.69% | 0.00% | Sep 2026 |
| Opaleye Management Inc | 1.38M | 1.46% | 0.00% | Jun 2026 |
Replimune Group Inc company profile
- Company name
- Replimune Group Inc
- Ticker
- REPL.US
- Exchange
- USA Stocks
- Listed since
- Jul 20, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 465
- Fiscal year end
- March
- Address
- 500 Unicorn Park Drive, Woburn, MA, United States, 01801
- Phone
- 781 222 9600
- Website
- replimune.com
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group Inc management
10- Dr. Sushil Patel Ph.D.CEO & Director · born 1971
- Ms. Emily Luisa HillChief Financial Officer · born 1980
- Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.Chief Medical Officer · born 1966
- Mr. Philip Astley-Sparke F.S.A.Executive Chairman · born 1971
- Ms. Nina AragamChief Operations Officer
- Mr. Andrew SchwendenmanChief Accounting Officer & Treasurer · born 1976
- Ms. Arleen GoldenbergHead of Investor Relations
- Mr. Shawn Glidden J.D.Chief Legal Officer
- Mr. Camilo Garcia M.A., M.B.A.Chief Human Resource Officer
- Mr. Paul BullockChief Manufacturing Officer & Framingham Site Head